About Contact Us Careers
Sign In

Gastroesophageal Reflux Disease (GERD) Market Size & Share, by Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication); Route of Administration (Oral, Parental); Distribution Channel (Hospital, Online, Retail); End-user (Hospital, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5075
  • Published Date: Jun 26, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Gastroesophageal Reflux Disease Market size is poised to reach USD 6 Billion by the end of 2035, growing at a CAGR of 2% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of gastroesophageal reflux diseases was over USD 5 Billion. The rising prevalence of gastrointestinal diseases over the world is set to propel the growth of the market. Recent statistics of WHO, in 2022 revealed that for every ten adults in the world, four suffer from functional gastrointestinal disorders.

The global gastroesophageal reflux disease market size is projected to also increase on account of increased awareness of the disease across the globe. Furthermore, the changing lifestyle of people toward sedentary behavior and the increasing tendency to self-medicate is also positively impacting the growth of the market. The availability of a strong medication pipeline is also slated to fuel the market gain.

Gastroesophageal Reflux Disease Market
Get more information on this report: Request Free Sample PDF

Gastroesophageal Reflux Disease (GERD) Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Cases of Esophageal Diseases – Esophageal diseases are a group of diseases that affects the esophagus, the tube responsible for carrying food from the mouth to the stomach. It causes heat burn during eating and swallowing problems and increases the chances of GERD in a human being.
  • Surge in Digestive Disorders – Regular drinking habits, lower physical exercise, and rising stress levels among the global population have led to an increase in digestive health disorders. This factor is estimated to fuel the global gastroesophageal reflux disease market size in the future. A report from 2022 stated that nearly 40% of Americans’ daily lives are disrupted by digestive troubles.
  • High Prevalence of Gastrointestinal (GI) Tract Diseases – Owing to the consumption of an unhealthy amount of junk along with the rising stress, anxiety, and panic levels among the middle age population is anticipated to bring lucrative growth opportunities for market growth in the next few years. It is observed that in the United States, irritable bowel syndrome is common with a prevalence of about 12% to 14%.
  • Increasing Desire for Eating Unhealthy Food Items – Fast-paced lives have propelled the working population for processed and junk food items owing to their easy availability, convenience, and taste. However, the outcome of eating unhealthy food daily is the development of gastroesophageal reflux disease (GERD). The consumption of ultra-processed food in the United States region has increased from around 54% in 2002 to approximately 57% in 2018.

Challenges

  • High Cost of the Treatment – GERD is classified as a chronic disease that requires long-term disease management which is costly. Pharmaceutical costs along with the physician and hospital fees, medicine prices, and surgery charges are directly linked with the treatment of gastroesophageal disease. This is estimated to hamper market growth during the forecast period.
  • Lack of Awareness Regarding the Disease
  • Unavailability of Qualified Professionals and Supporting Staff

Gastroesophageal Reflux Disease Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~2%

Base Year Market Size (2022)

~ USD 5 Billion

Forecast Year Market Size (2035)

~ USD 6 Billion

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Gastroesophageal Reflux Disease (GERD) Segmentation

Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication)

The antacids segment value is poised to be the greatest among the others with a market share of 26% by 2035. This is due to the fast relief that antacids provide. It is quick and very effective for all the patients. Antacids are also useful in various conditions which include heartburn, acid indigestion, hyperacidity, upset stomach, and other related illnesses. Furthermore, the growth in the awareness level about self-medication has led to the higher consumption of antacids rather than visiting healthcare systems. In addition to other benefits, antacids deliver fast positive results and have minimal to no side effects, and are even safe for pregnant women. All these factors couple up to create a positive outlook for segment expansion in the next few years.

Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

The hospital pharmacy sub-segment is set to register a significant growth rate in the distribution channel segment in 2035. The major factor projected to help in the growth of the segment size is the rising number of pharmacies in hospitals which increases the ease for the patients visiting hospitals. In addition, the favorable reimbursement policies in hospital pharmacies are also estimated to drive segment size. Also, the presence of trained and qualified staff and the associated trust in the hospitals is anticipated to further help in the expansion of the segment.

Our in-depth analysis of the global market includes the following segments:

    Drug Type
  • Antacids
  • Proton Pump Inhibitors
  • H2 Receptor Blocker
  • Pro Kinetic Agents
  • Dopamine Receptor Antagonist
  • EndoCinch
  • Stretta
  • EsophyX
  • Transoral Incisionless
  • Fundoplication

    Route of Administration
  • Oral
  • Parental

    Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

    End-Users
  • Hospital
  • Homecare
  • Specialty Clinics
 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Gastroesophageal Reflux Disease (GERD) Market - Regional Synopsis

North American Market Forecast

The GERD market in North America is projected to hold a significant revenue share of 35% with a considerable growth rate by 2035. The primary factor for the market expansion is the rising aging population in the region which are more prone to gastrointestinal problems. Furthermore, the rising awareness regarding drug therapies along with the high rate of acceptance of therapy for GERD diseases is also estimated to bring growth opportunities for market expansion in the region.

APAC Market Analysis

The Asia Pacific gastroesophageal reflux disease market is estimated to grow at a notable pace and holds almost 24% market share by the end of the forecast timeline. The rising awareness about health and fitness among the people in the region and the increase in health spending is considered to be the major factor for market growth in the region during the next years. In addition, the expenditure on healthcare from foreign countries is increasing which is favoring the new drug development for GERD treatment in the region.

Research Nester
Gastroesophageal Reflux Disease Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Gastroesophageal Reflux Disease (GERD) Landscape

top-features-companies
    • AstraZeneca PLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eisai Co., Ltd.
    • GSK plc.
    • Takeda Pharmaceutical Company Limited.
    • Ironwood Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • SFJ Pharmaceuticals
    • Sebela Pharmaceuticals
    • Phathom Pharmaceuticals, Inc.
    • Camber Pharmaceuticals, Inc.

In the News

  • AstraZeneca PLC has successfully signed the global license agreement with KYM Biosciences Inc. for the development of CMG901, an antibody-drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
  • Eisai Co., Ltd. and Bliss Biopharmaceutical Co., Ltd. have joined hands to develop BB-1701, an antibody-drug conjugate (ADC). This new drug is expected to have anti-tumor effects on breast, lung, and other solid tumors.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5075
  • Published Date: Jun 26, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

The market size of solar updraft towers is anticipated to attain a CAGR of ~2% over the forecast period, i.e., 2023 – 2035.

The major players in the market are AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, route of administration, distribution channel, end-user, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The high costs of the treatment along with the unavailability of a professional and skilled workforce and the lack of awareness regarding the disease are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Gastroesophageal Reflux Disease Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying